AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. [electronic resource]
Producer: 20170309Description: 272-9 p. digitalISSN:- 1473-1150
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers, Tumor -- genetics
- Clinical Trials, Phase III as Topic
- Colorectal Neoplasms -- drug therapy
- Disease-Free Survival
- Female
- Fluorouracil -- adverse effects
- Genetic Association Studies
- Genotype
- Humans
- Male
- Middle Aged
- Multidrug Resistance-Associated Protein 2
- Neoplasm Metastasis
- Organoplatinum Compounds -- adverse effects
- Oxaliplatin
- Pharmacogenomic Variants -- genetics
- Phenotype
- Polymorphism, Single Nucleotide
- Randomized Controlled Trials as Topic
- Retrospective Studies
- Risk Factors
- Scandinavian and Nordic Countries
- Time Factors
- Transaminases -- genetics
- Treatment Outcome
- Xeroderma Pigmentosum Group D Protein -- genetics
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.